2026-12612NoticeWallet

FTC Seeks Comment on Drug Company Settlement Deal

Published Date: 6/23/2026

Notice

Summary

The Federal Trade Commission is asking for your thoughts on a deal with Aurobindo and Lannett, two drug companies accused of unfair competition. The companies agree to stop certain practices that hurt competition, helping keep medicine prices fair. You have until July 23, 2026, to share your opinion before the deal is final.

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

Divestiture to Restore Drug Competition

The FTC says Aurobindo's proposed $250 million acquisition of Lannett could raise prices for four generic medicines, so the companies must sell all rights and assets for those products to Quagen Pharmaceuticals Inc. The four products are mycophenolate mofetil oral suspension, niacin extended release tablets, pilocarpine tablets, and rabeprazole sodium delayed release tablets. The Consent Agreement requires the divestitures no later than 10 days after the Acquisition closes, and if Quagen is unacceptable the sellers must unwind and divest to a Commission-approved buyer within six months.

Your PRIA Score

Score Hidden

Personalized for You

How does this regulation affect your finances?

Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.

Free to start

Key Dates

Published Date
Comments Due
6/23/2026
7/23/2026

Department and Agencies

Department
Independent Agency
Agency
Federal Trade Commission
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register